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Around 20 years ago, we started some work on evidence-
based medicine that our medical colleagues called “working like 
ants building anthills”. We began with talks and educational 
articles on the importance of clinical epidemiology for improv-
ing clinical research and, at the same time, we emphasized 
the importance of systematic reviews for human health.1,2 In 
parallel, we conducted prospective cohort studies on hyper-
tensive pregnant women that showed the serious situation 
regarding chronic hypertension during pregnancy within our 
environment. Whereas gestational hypertension is taken in the 
fi rst world to have few clinical consequences, here it has been 
associated with severe maternal-fetal complications in almost 
60% of the cases.3
On the basis of this study, we carried out a large clinical 
trial on the use of low doses of aspirin (80 mg/day) for prevent-
ing preeclampsia and its consequences.4 This trial included 
1000 patients, of whom 500 were hypertensive and showed 
that aspirin had no major effect regarding the prevention of 
preeclampsia, contrary to what had been suggested by articles 
published in the leading journals Lancet5 and New England 
Journal of Medicine.6 In parallel, we developed the Eclampsia 
Trial with colleagues in Oxford and Latin American and African 
countries. This showed that the effectiveness of the traditional 
remedy magnesium sulfate was greater than the effectiveness 
of all the drugs launched and adopted over the 90 years that 
followed the initial use of magnesium sulfate. The Eclampsia 
Trial changed the way in which convulsions due to eclampsia 
were treated in countries where more than three billion peo-
ple live. It was considered to be the best clinical trial of the 
twentieth century in editorials published by leading medical 
journals.7,8 Today, it is the standard treatment for convulsions 
due to eclampsia.8,9 In subsequent work by the same group 
(the Magpie Trial), it was found that administration of mag-
nesium to pregnant women with hypertension and proteinuria 
reduced the chance that the patients would develop eclampsia 
by 67%.10 It should be added, incidentally, that magnesium 
sulfate is extremely inexpensive and is a substance that forms 
a large proportion of the earth’s crust! 
A systematic review conducted by us and colleagues in 
South Africa (Justus Hofmeyr) and the United Kingdom (Lelia 
Duley) in 199811 showed the possible benefi ts of calcium sup-
plementation in preventing preeclampsia and maternal-fetal 
morbidity among pregnant women with low calcium intake 
(calcium-poor) who were at high risk of preeclampsia.
On the basis of this review, the World Health Organiza-
tion (WHO) started to recommend calcium supplementation 
for the diet of pregnant women. There is no evidence of risks. 
More recently, WHO itself funded a mega-trial to compare 
calcium supplementation during pregnancy with placebo, 
among low-risk patients, which also showed that calcium 
supplementation decreased the incidence of preeclampsia and 
maternal-fetal morbidity.12 With the data from this mega-trial, 
we improved the systematic review that was initially published 
in the Cochrane Library and submitted it for publication in 
the British Medical Journal (Hofmeyr J, Atallah AN and Duley 
L), where it has been accepted and is awaiting publication. 
Through this, practically all pregnant women around the world 
will be advised to adopt a calcium-rich diet (or to take calcium 
carbonate, between 500 mg/day and 2,000 mg/day), in order 
to prevent hypertensive complications during pregnancy. Also 
recently, the PARIS group, constituted by colleagues who took 
part in the abovementioned clinical trials, met in Oxford to 
discuss the systematic review on the use of aspirin in low doses 
for preventing preeclampsia. The meta-analyses included are 
the Collaborative Study for Prevention of Preeclampsia with 
Aspirin (Estudo Colaborativo para Prevenção da Pré-eclâmpsia 
com Aspirina, ECPPA)4 and data on more than 29,000 cases 
that had been included in clinical trials on this subject. This 
systematic review, which brings together data on the individual 
cases of around 30,000 patients and has been accepted for 
publication by the Lancet, is a model of what we can call the 
quintessence of evidence: it defi nes the effect. It should be 
compared with the systematic review with meta-analysis that 
ECPPA published in 19964 and with the other review that 
was published in the Cochrane Library.11 Through this, the 
uncertainties on the subject are being progressively reduced, 
in an appropriate manner.
Thus, over the last 20 years, we have learned much 
about how to obtain evidence from research with adequate 
methodology and through systematic reviews of the lit-
erature. It can be said in passing that all the studies cited 
here were preceded by systematic reviews; the study on 
aspirin was preceded and complemented by a systematic 
review. All this learning was shared with undergraduate and 
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postgraduate students and with practicing 
professionals and medical entities through 
the Scientific Board of the São Paulo 
Medical Association (Associação Paulista de 
Medicina, APM), and also with healthcare 
professionals in all fields.
In October of this year, many stories like 
these and the consequent evidence obtained 
will be presented at the Fifteenth Cochrane 
Colloquium, “Evidence-Based Healthcare 
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for all”, which is to be held in São Paulo from 
October 23 to 28, 2007. All perspectives, 
whether from patients, doctors, healthcare 
professionals, judges and attorneys, managers 
responsible for healthcare companies, health 
departments of states and municipalities, 
health ministries of dozens of countries, or 
international entities like WHO and the 
Pan-American Health Organization (PAHO), 
will be integrated for the benefi t of the best 
evidence in healthcare for all. Mark it in your 
diaries: http://www.colloquiumbrasil.info/ 
— www.centrocochranedobrasil.org.
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